Bank of New York Mellon’s Verve Therapeutics VERV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.48M | Sell |
220,788
-4,246
| -2% | -$47.7K | ﹤0.01% | 2632 |
|
|
2025
Q1 | $1.03M | Buy |
225,034
+4,532
| +2% | +$20.7K | ﹤0.01% | 3038 |
|
|
2024
Q4 | $1.24M | Buy |
220,502
+5,262
| +2% | +$29.7K | ﹤0.01% | 3007 |
|
|
2024
Q3 | $1.04M | Sell |
215,240
-59,633
| -22% | -$289K | ﹤0.01% | 3116 |
|
|
2024
Q2 | $1.34M | Buy |
274,873
+49,922
| +22% | +$244K | ﹤0.01% | 3018 |
|
|
2024
Q1 | $2.99M | Buy |
224,951
+24,776
| +12% | +$329K | ﹤0.01% | 2556 |
|
|
2023
Q4 | $2.79M | Buy |
200,175
+12,983
| +7% | +$181K | ﹤0.01% | 2657 |
|
|
2023
Q3 | $2.48M | Buy |
187,192
+407
| +0.2% | +$5.4K | ﹤0.01% | 2688 |
|
|
2023
Q2 | $3.5M | Buy |
186,785
+15,636
| +9% | +$293K | ﹤0.01% | 2516 |
|
|
2023
Q1 | $2.47M | Sell |
171,149
-3,243
| -2% | -$46.8K | ﹤0.01% | 2681 |
|
|
2022
Q4 | $3.37M | Buy |
174,392
+4,514
| +3% | +$87.3K | ﹤0.01% | 2557 |
|
|
2022
Q3 | $5.84M | Buy |
169,878
+66,322
| +64% | +$2.28M | ﹤0.01% | 2214 |
|
|
2022
Q2 | $1.58M | Sell |
103,556
-12,231
| -11% | -$187K | ﹤0.01% | 2962 |
|
|
2022
Q1 | $2.64M | Buy |
115,787
+36,652
| +46% | +$836K | ﹤0.01% | 2784 |
|
|
2021
Q4 | $2.92M | Buy |
79,135
+22,877
| +41% | +$844K | ﹤0.01% | 2761 |
|
|
2021
Q3 | $2.64M | Buy |
+56,258
| New | +$2.64M | ﹤0.01% | 2830 |
|